Download this assay page in pdf format.
Analyte: Glucagon-Like Peptide 1 Active
Specimen Type: Plasma from BD P700 or P800, EDTA Plasma with preservatives; contact PBI for collection instructions
Optimum Volume: 0.5 mL
|6 hours||6 months||6 months|
Reporting units: pmol/L
Method: Electrochemiluminescent Immuno
Biological or Clinical Significance:
Glucagon-like peptide 1 (GLP-1) is a 3.5 kD incretin hormone secreted primarily from the enteroglucagon-producing L-cells in the small intestine. The main actions of GLP-1 are stimulation of insulin secretion, reduction of gastric emptying and inhibition of glucagon secretion. GLP-1 also appears to be a physiological regulator of appetite and food intake. Decreased secretion of GLP-1 may contribute to the development of obesity, and exaggerated secretion could be responsible for postprandial reactive hypoglycemia.GLP-1 (7-36) amide and GLP-1 (7-37) are the biologically active forms of GLP-1. In vivo, the active forms are rapidly degraded by the dipeptidyl peptidase IV (DPP-IV), therefore blood collected for assays that quantitatively measure active forms of GLP-1 must be immediately preserved with DPP-IV inhibitors.
Principle of Test Method:
The GLP-1 active assay is an ultra-sensitive kit designed to quantify human active GLP-1 in human plasma, serum, and other biological media. This immunoassay employs electrochemilunimescent detection.
1. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM. Human duodenal enteroendocrine cells: Source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006; 290: E550-559.
2. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an n-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
3. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53:654-662.
4. Kim BJ, Carlson OD, Jang HJ, Elahi D, Berry C and Egan JM. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005, 90: 6665-6671